Baxter International Inc.

Baxter International Inc.(BAX)股票分析

$25.405

+0.495 (+1.95%)收盤時

Loading chart…
最高
26.025
開盤
25.110
成交量加權均價
25.45
成交量
12.43M
市值
17.08B
最低
24.930
成交金額
316.48M
企業價值/稅息折舊攤銷前利潤(TTM)
7.73

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others.

AI 分析 of Baxter International Inc. (BAX)

持有

Baxter International Inc is currently priced at $25.30, which is below the average analyst price target of $27.75. The company has shown a year-to-date change of +29.74%, indicating strong performance. However, the forward P/E ratio is 11.57, which suggests it may not be undervalued. The main risk is the recent earnings guidance, which has been lowered by some analysts, reflecting uncertainty in future growth.

估值指標

Baxter International Inc.(BAX)目前預期本益比為 12.38,5 年平均預期本益比為 13.80。

預期本益比

合理
5 年均值 P/E
13.80
目前P/E
12.38
高估
17.34
低估
10.25

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
11.73
目前EV/EBITDA
7.73
高估
14.89
低估
8.56

預期股價營收比

合理
5 年均值 P/S
1.47
目前P/S
1.10
高估
2.01
低估
0.94

Alphio AI 對 BAX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%BAX

$28.00

情境價格

基

基準

基準 · 50%BAX

$25.49

情境價格

悲

悲觀

悲觀 · 25%BAX

$18.18

情境價格

持有 BAX 的大戶

E

Edmond de Rothschild Asset Management (France)

+ 持有BAX

+6.62%

3個月報酬率

R

RWC Partners Limited

+ 持有BAX

+2.89%

3個月報酬率

G

Greenhaven Associates Inc

+ 持有BAX

+1.92%

3個月報酬率

F

First Pacific Advisors, LP

+ 持有BAX

+0.18%

3個月報酬率

T

Tontine Management, LLC

+ 持有BAX

-28.65%

3個月報酬率

事件時間軸

2026-10-20 (ET)

12:30:00

U.S. 10-Year Treasury Yield Falls to Near One-Month Lows

2026-08-19 (ET)

08:30:00

Baxter International Appoints John Rogers as CFO

2026-08-04 (ET)

09:00:00

Baxter International Launches Cash Tender Offers Up to $500M

2026-07-30 (ET)

09:00:00

Microsoft's Strong Earnings Boosts Stock Futures Rebound

資訊

BAX 常見問題 —— 由 Alphio AI 解答

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Baxter International Inc is currently priced at $25.30, which is below the average analyst price target of $27.75. The company has shown a year-to-date change of +29.74%, indicating strong performance. However, the forward P/E ratio is 11.57, which suggests it may not be undervalued. The main risk is the recent earnings guidance, which has been lowered by some analysts, reflecting uncertainty in future growth.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易